Literature DB >> 12828259

Evaluation of serum biochemical markers of bone metabolism for early diagnosis of nonunion and infected nonunion fractures in rabbits.

Louise L Southwood1, David D Frisbie, Chris E Kawcak, C Wayne McIlwraith.   

Abstract

OBJECTIVE: To evaluate the use of serum concentrations of biochemical markers of bone metabolism (osteocalcin [OC], bone-specific alkaline phosphatase [BS-ALP], and deoxypyridinoline [DPYR]) to compare healing in infected versus noninfected fractures and in fractures with normal repair versus delayed (nonunion) repair in rabbits. ANIMALS: 32 female 9- to 10-month-old New Zealand White rabbits. PROCEDURE: A femoral fracture defect was made in each rabbit. Rabbits were assigned to the following groups: the bone morphogenetic-2 gene treatment group with either noninfected nonunion or infected (ie, inoculation of defects with Staphylococcus aureus) nonunion fractures or the luciferase (control) gene treatment group with either noninfected nonunion or infected nonunion fractures. Serum samples were obtained before surgery (time 0) and 4, 8, 12, and 16 weeks after surgery. Callus formation and lysis grades were evaluated radiographically at 16 weeks.
RESULTS: Serum OC and BS-ALP concentrations decreased from time 0 at 4 weeks, peaked at 8 weeks, and then decreased. Serum DPYR concentration peaked at 4 weeks and then decreased, independent of gene treatment group or fracture infection status. Compared with rabbits with noninfected fractures, those with infected fractures had lower serum OC and BS-ALP concentrations at 4 weeks, higher serum OC concentrations at 16 weeks, and higher serum DPYR concentrations at 4, 8, and 16 weeks. Combined serum OC, BS-ALP, and DPYR concentrations provided an accuracy of 96% for prediction of fracture infection status at 4 weeks. CONCLUSIONS AND CLINICAL RELEVANCE: Measurement of multiple serum biochemical markers of bone metabolism could be useful for clinical evaluation of fracture healing and early diagnosis of osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828259     DOI: 10.2460/ajvr.2003.64.727

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

Review 1.  Recent advances in the use of serological bone formation markers to monitor callus development and fracture healing.

Authors:  Marlon O Coulibaly; Debra L Sietsema; Travis A Burgers; Jim Mason; Bart O Williams; Clifford B Jones
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

2.  Diabetic foot osteomyelitis: bone markers and treatment outcomes.

Authors:  Humaa A Nyazee; Kristina M Finney; Molly Sarikonda; Dwight A Towler; Jeffrey E Johnson; Hilary M Babcock
Journal:  Diabetes Res Clin Pract       Date:  2012-04-27       Impact factor: 5.602

3.  Serum N-terminal telopeptide of type I collagen as an early marker of fracture nonunion in rabbits.

Authors:  Jian-Ping Lin; Zhan-Jun Shi; Ning-Jiang Shen; Jian Wang; Zao-Min Li; Jun Xiao
Journal:  Exp Ther Med       Date:  2016-10-26       Impact factor: 2.447

4.  Increased serum OPG in atrophic nonunion shaft fractures.

Authors:  Daniele Marchelli; Luca P Piodi; Costantino Corradini; Luca Parravicini; Cesare Verdoia; Fabio M Ulivieri
Journal:  J Orthop Traumatol       Date:  2009-03-19

5.  N-terminal telopeptides of type I collagen and bone mineral density for early diagnosis of nonunion: An experimental study in rabbits.

Authors:  Jian-Ping Lin; Zhan-Jun Shi; Ning-Jiang Shen; Jian Wang; Zao-Min Li; Jun Xiao
Journal:  Indian J Orthop       Date:  2016 Jul-Aug       Impact factor: 1.251

6.  Serum procollagen type 1 N propeptide: A novel diagnostic test for diabetic foot osteomyelitis - A case-control study.

Authors:  Oliver G Hayes; Venkat N Vangaveti; Usman H Malabu
Journal:  J Res Med Sci       Date:  2018-05-30       Impact factor: 1.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.